$HIMS

HIMSHims & Hers Health, Inc. Class A Common Stock

YouTube 频道最近怎么谈 Hims & Hers Health(HIMS)?

过去 30 天(截至 11-18),7 个 YouTube 频道谈到 Hims & Hers Health(HIMS),共 10 条。最近一条:Schwab Network,2026-11-18。

本窗口内的全部观点与内容

截至 11-18
11-18
Schwab Network发布 2026-11-18
《Wednesday's Final Takeaways: Gold at 52-Week Lows, Housing Market Mixed》
$HIMS中性
AI 摘要 · HIMS 推出 Peptides Plus,包含五种联合疗法,有望在肽类需求上升之际吸引传统远程医疗之外的新客户并带来经常性收入;但首批疗法均未获 FDA 批准,HIMS 表示安全性、有效性和剂量仍不确定,监管与科学风险可能实质性威胁其增长计划。

Hims&Hers 可能错过了“多肽热潮之夏”,但随着它推出新的“Peptides Plus”平台,提供五种组合疗法,针对从精力与恢复到细胞健康的各种需求,一个“多肽热潮之冬”可能即将到来。

Hims&Hers may have missed out on the " hot peptide summer," but there may be a " hot peptide winter" coming, as it launches its new "Peptides Plus" platform offering five combination therapies targeting everything from energy and recovery to cellular health.

这一举措出台之际,多肽的需求正在上升,但这里存在一个重大障碍。最初的治疗方案均未获得美国食品药品监督管理局(FDA)的批准,公司自己也承认,关于其安全性、有效性和合适剂量,仍有很多需要了解。

This move comes at a time when demand for peptides is increasing, but there is a major obstacle here . None of the initial treatments are approved by the Food and Drug Administration (FDA), and the company itself acknowledges that there is still much to learn about their safety, effectiveness, and appropriate dosages .

11-17
Verified Investing发布 2026-11-17
《MAJOR EARNINGS FOR NVIDIA (Silver Bottom?)》
$HIMS看涨
AI 摘要 · HIMS 自 5 月前不久起处于下跌趋势,尽管业绩尚可,股价仍下跌且仍在下跌;说话者只会在其跌至约 18 美元时买入,视其为潜在支撑区域。

所以,在市场整体小幅反弹的情况下,我在找一些可能下跌且位置稍低的标的,那就是HIMS。从今年5月之前一路延伸过来,有一条漂亮的下降趋势线,穿过这里,穿过这里,然后最终在下方寻找潜在支撑区域。

So with the markets generally kind of bouncing a little bit, I'm looking at something that might fall and is a little lower and that's HIMS HIMS. You have a nice downs sloping trend line from all the way back here just before May of this year coming through here coming through here and then finally looking for an area for potential support down here.

11-13
《NVDA Fallout: Where Is the Smart Money Going? | Market Pulse Nov. 13, 2026》
$HIMS看跌
AI 摘要 · HIMS 曾长期上涨,但在模糊记得的账户相关问题之后,连续数周下跌,并在衰竭缺口处跳空低开;说话者得出结论,它尚未恢复。

我们来看看“Hems”这家公司。它叫“Hems & Hers Health”。现在看这张图,不是吗?很明显,这张图已经向上趋势了很长时间。他们遇到了账户之类的一些问题。我记不清了。

但看看那连续数周的下跌,直到该股最终跳空低开,那是一个衰竭缺口。它真的没能恢复,对吧?

Let's take a look at the "Hems" company. It's called " [17:18] Hems & Hers Health". Now look at this [17:21] graph, don't you? It is clear that [17:24] this chart has been trending upwards for a long time [17:27] .

They encountered some problems with the accounts or something like that [17:29] . I can't remember. But [17:32] look at all those consecutive weeks of [17:35] decline, until the stock eventually gapped down [17:37] , and that was an exhaustion gap. He [17:39] really couldn't recover, did he?

Parkev Tatevosian, CFA发布 2026-11-13
《Why Is Hims Stock Crashing, and is it a Buying Opportunity?》
$HIMS看涨
AI 摘要 · HIMS 仍是买入机会,但他的信心已从中等降至低,原因是费用增速快于收入:G&A 几乎翻倍至 1.515 亿美元,营业利润从 1180 万美元降至 -6600 万美元,经营现金流从 2.39 亿美元降至 1.19 亿美元,因此约 18% 的下跌是合理的。尽管收入增长 49%、订阅用户增长 13%、每订阅用户收入提高 30%,但在 19 美元价位,该股相对他略高于 22 美元的合理价值以及 25.4 倍的远期市盈率仍被低估。

Hems & Hers 公布了季度财务业绩,令股市投资者感到失望。营收增长了49%,订阅用户增长了13%,但费用也增加了,现金流则大幅下降。

Hems & Hers announced quarterly financial results that disappointed investors in the stock market. Revenues increased by 49% and subscribers by 13%, but expenses also increased and cash flow decreased significantly.

投资者惩罚了这只股票,在公司公布这些数据后的第二天,股价下跌了约19%。所以我想分享一下我对 Heams & Hers 股票的评级,我认为这次股价下跌后是否构成了买入机会,以及我对该公司公允价值的估计。

Investors punished the stock, which fell by about 19 % the day after the company announced these figures. So I wanted to share my rating of Heams & Hers stock, whether I think this represents a buying opportunity after the price drop , and what my estimate of the company's fair value is.

他说在等
电话会议记录中对一般及行政费用(G&A)为何近乎翻倍的解释
成本上升与收购相关,而非结构性问题
下一次财报电话会议记录
支持买入逻辑
11-10
《Hims & Hers Collapses 30% In a Week》
$HIMS看涨
AI 摘要 · HIMS 在令人失望的季度后下跌 18%:订阅用户环比减少约 10 万,受品牌 GLP-1 产品结构影响,毛利率从 83% 降至 57%,第四季度营收指引小幅下滑,全年调整后 EBIT 指引被下调。说话者并未卖出,仍认为 HIMS 是值得持有 5-10 年的优秀公司,依据是其更高定价的订阅、TRT 与肽类策略以及类似 Costco 的健康订阅模式,管理层把希望押在 2027 年第一季度;短期订阅用户增长与竞争仍存疑问,下一季度指引很重要。

他和他妻子的公司周一公布了财报,周二盘后交易中,两人的股票下跌了18%。投资者不喜欢他们在财报中听到的内容。从很多方面来看,这份财报确实令人失望。订阅用户数环比下降。毛利率继续承压。

而且管理层表示,他们实际上并没有花那么多钱去获取那些新客户。这就是增长真正放缓的原因。

Shares of his and hers are down 18% in late trading on Tuesday after their company reported earnings on Monday. The investors did not like what they heard from the earnings report.

In a lot of ways, the report was really disappointing. The number of subscribers was down quarter over quarter. Gross margins continued to be under pressure. And management said that they were actually not spending as much to bring in those new customers. That's why growth really slowed.

他说在等
下一季度关于盈利性获客与增长的指引
恢复以盈利性增长为前提的获客
下一季度下一次财报电话会/指引
支持长期持有的论点
The Motley Fool发布 2026-11-10
《Stock Market Update: Rising Rates & Falling Stocks》
$HIMS中性
AI 摘要 · HIMS是一个好坏参半的判断:季度增长跃升至49%,部分来自收购,估值倍数相对合理,每用户收入从两个季度前的80美元升至105美元;但利润率持续下滑,随着营销收缩,用户数减少约10万至279万,同时竞争加剧、模式依赖营销。一种看法是它太难、已放弃;另一种看法是在10年视角下近期噪音无关紧要,并看好其计划中的美国产肽类产品。

Hims and Hers 过去一个月下跌了约 40%。他们是转向 AI 云了吗?还是说,对,他们需要,他们需要做那个 Allirds 转型。对,那大概应该,他们正在招聘大量 AI 人员。

只是还没在他们的产品里看到这一点。不过他们今天大幅下跌,截至我们录制时大约跌了 18%。

him and hers down about 40% in the past month. Did they pivot to uh AI cloud or Yeah, they need to Yeah, they need to do the uh the Allirds pivot. Yeah, that should probably They're hiring a lot of AI people. um just haven't seen that in in their products yet.

Uh but big move down for them today about 18% as we're recording right now.

Schwab Network发布 2026-11-10
《HIMS Earnings Stumble on Double Miss, Guidance Becomes New Focus》
$HIMS中性
AI 摘要 · 在意外亏损、营收与订阅用户数双双不及预期、指引低于市场共识之后,HIMS 下跌 13.5% 至约 19 美元,年初至今跌幅接近 40%。说话者预计其将在当前水平附近企稳,20 美元为主要支撑位,并卖出一份 12 月虚值看跌期权价差;他认为增长将持续但放缓,肽类业务的利好正在消退,两位数增长可能已经结束,但公司本身依然稳健。

我们来看一下 Hims and Hers 的走势图。这家医疗健康公司本季度意外转为亏损,并收窄了全年销售展望,股价因此承压。

Let's focus on the chart for Hims and Hers. Shares are under pressure after the healthcare company swung to a surprised loss for the quarter and narrowed its fullear sales outlook.

这是我们在一年走势图上看到的情况。它已经回落了相当多。Hims and Hers 目前下跌约13.5%,股价在19美元出头。所以这是今天早盘交易的焦点。

So here is a look at what we're seeing on the one year. It's come off quite considerably. We're down about 13.5% trading at $19 and change on him and hers. So this is the focus of the morning trade.

11-09
已显示 8 / 本页 10 条
看这只股票的全部记录